drugset
Drugs / remogliflozin etabonate
last change Jun 2021 re-read 9 days ago

remogliflozin etabonate

also known as GSK189075 · BHV-091009 · Etabonate de remogliflozine · Etabonato de remogliflozina · GSK189075A

Small molecule targets SLC5A2 via inhibition

Developed for
type 2 diabetes mellitus · obesity disorder · type 1 diabetes mellitus
Investigated by
GlaxoSmithKline · BHV Pharma · Integrium

Trials 18

today NCT02537470 · Ph 2 NCT00575159 · Ph 2 NCT00671424 · Ph 1 NCT00625859 · Ph 1 NCT00559884 · Ph 1 NCT00532610 · Ph 1 NCT00519480 · Ph 1 NCT00495469 · Ph 2 NCT00501462 · Ph 1 NCT00501930 · Ph 1 NCT00504816 · Ph 1 NCT00501397 · Ph 1 NCT00500331 · Ph 2 NCT00501683 · Ph 1 NCT00494767 · Ph 1 NCT00376038 · Ph 1 NCT00291356 · Ph 2 NCT01571661 · Ph 1
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 113 trials
Phase 1 NCT00671424 Mar → May 2008 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00625859 Jan → Apr 2008 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00559884 Nov 2007 → ? type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00519480 Sep 2007 → Apr 2008 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00532610 Sep 2007 → Feb 2008 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00501462 Jul 2007 → Mar 2008 impaired renal function disease, type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00501930 Apr 2007 → ? type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00504816 Apr 2007 → Jan 2008 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00501397 Feb 2007 → ? type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00501683 Nov 2006 → ? type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 25 trials · 2 met primary
Phase 2 NCT02537470 Jul 2015 → Aug 2016 type 2 diabetes mellitus BHV Pharma Completed No outcome recorded
Phase 2 NCT00575159 Mar → Dec 2008 type 1 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00495469 Aug 2007 → Jun 2008 type 2 diabetes mellitus GlaxoSmithKline Completed Met primary
Phase 2 NCT00500331 Jan 2007 → Feb 2008 type 2 diabetes mellitus GlaxoSmithKline Completed Met primary
Phase 2 NCT00291356 Jan → May 2006 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as remogliflozin etabonate “Assessment of safety and tolerability of remogliflozin etabonate (GSK189075)” PMID 34120651 ↗ Jun 2021
2

NCT02537470 ↗

NCT00671424 ↗
Known as BHV-091009 ChEMBL registry synonym — accepted as the source's own label CHEMBL2028665 ↗
Known as Etabonate de remogliflozine ChEMBL registry synonym — accepted as the source's own label CHEMBL2028665 ↗
Known as Etabonato de remogliflozina ChEMBL registry synonym — accepted as the source's own label CHEMBL2028665 ↗
Known as GSK189075 “Assessment of safety and tolerability of remogliflozin etabonate (GSK189075)” PMID 34120651 ↗ Jun 2021
15

“Remogliflozin etabonate (GSK189075)” NCT00671424 ↗

NCT00501397 ↗

NCT00494767 ↗

NCT00575159 ↗

NCT00625859 ↗

NCT00291356 ↗

NCT00501683 ↗

NCT00504816 ↗

NCT00501462 ↗

NCT00532610 ↗

Show 5 more sources
Known as GSK189075A “GSK189075A 20mg” NCT01571661 ↗
Action Inhibit “remogliflozinetabonate, an SGLT2 inhibitor” PMID 34120651 ↗ Jun 2021
1

“Sodium/glucose cotransporter 2 inhibitor” CHEMBL2028665 ↗
Modality Small molecule — CHEMBL2028665 ↗
Route Oral “GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth” NCT00291356 ↗
Target SLC5A2 “Sodium/glucose cotransporter 2 inhibitor” CHEMBL2028665 ↗